NURO - NeuroMetrix Inc Stock Price, Fair Value and News

4.19USD0.00 (0.00%)Delayed as of 16 May 2024, 12:48 pm ET

Market Summary

USD4.190.00

Delayedas of 16 May 2024, 12:48 pm

0.00%

NURO Stock Price

View Fullscreen

NURO RSI Chart

NURO Valuation

Market Cap

8.4M

Price/Earnings (Trailing)

-1.06

Price/Sales (Trailing)

1.6

EV/EBITDA

-0.72

Price/Free Cashflow

-1.17

NURO Price/Sales (Trailing)

NURO Profitability

Operating Margin

61.97%

EBT Margin

-189.89%

Return on Equity

-42.57%

Return on Assets

-38.64%

Free Cashflow Yield

-85.77%

NURO Fundamentals

NURO Revenue

Revenue (TTM)

5.3M

Rev. Growth (Yr)

-36.6%

Rev. Growth (Qtr)

-17.01%

NURO Earnings

Earnings (TTM)

-8.0M

Earnings Growth (Yr)

-92.45%

Earnings Growth (Qtr)

-83.66%

Breaking Down NURO Revenue

52 Week Range

0.604.19

(Low)(High)

Last 7 days

-5.4%

Last 30 days

19.0%

Last 90 days

26.2%

Trailing 12 Months

346.2%

How does NURO drawdown profile look like?

NURO Financial Health

Current Ratio

10.91

NURO Investor Care

Shares Dilution (1Y)

105.27%

Diluted EPS (TTM)

-6.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.3M	0	0	0
2023	7.7M	7.2M	6.4M	5.9M
2022	8.4M	8.3M	8.2M	8.3M
2021	7.4M	8.2M	8.2M	8.3M
2020	6.5M	6.5M	6.5M	7.4M
2019	17.0M	14.6M	13.0M	10.1M
2018	17.5M	17.0M	17.1M	16.0M
2017	14.1M	15.7M	15.9M	17.1M
2016	8.3M	9.7M	11.0M	12.0M
2015	5.5M	5.3M	6.0M	7.3M
2014	5.2M	5.4M	5.5M	5.5M
2013	6.9M	5.8M	5.4M	5.3M
2012	9.6M	9.2M	8.4M	7.6M
2011	13.2M	12.0M	11.1M	10.4M
2010	0	22.1M	18.0M	13.9M
2009	0	0	0	26.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeuroMetrix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	higgins thomas t	acquired	2,226	4.47	498	senior vice president, cfo
May 02, 2024	gozani shai	acquired	2,842	4.47	636	president & ceo
May 02, 2024	higgins thomas t	sold (taxes)	-375	4.47	-84.00	senior vice president, cfo
May 02, 2024	gozani shai	sold (taxes)	-353	4.47	-79.00	president & ceo
Apr 30, 2024	katz nancy e	acquired	23,580	4.37	5,396	-
Apr 30, 2024	goodman david	acquired	23,580	4.37	5,396	-
Apr 30, 2024	fluegel bradley m	acquired	23,580	4.37	5,396	-
Apr 30, 2024	van avermaete david	acquired	23,580	4.37	5,396	-
Apr 22, 2024	horowitz joshua	sold	-4,580	4.58	-1,000	-
Apr 18, 2024	horowitz joshua	acquired	-	-	16,438	-

Which funds bought or sold NURO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	58.63	3,258	6,991	-%
May 14, 2024	Cerity Partners LLC	sold off	-100	-108,000	-	-%
May 13, 2024	FMR LLC	new	-	17.00	17.00	-%
May 13, 2024	Accent Capital Management, LLC	unchanged	-	406	2,656	-%
May 13, 2024	UBS Group AG	added	1,791	8,753	9,163	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-84,000	-	-%
May 10, 2024	BlackRock Inc.	reduced	-1.14	3,049	21,305	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	12.5	9.00	38.00	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-17.71	-697	23,693	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	9,831	64,277	-%

Are Funds Buying or Selling NURO?

Are funds buying NURO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NURO

No. of Funds

Unveiling NeuroMetrix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 04, 2024	rs fund lp	9.9%	150,000	SC 13D/A
Feb 27, 2024	fields ephraim g	9.3%	140,024	SC 13D
Feb 26, 2024	rs fund lp	14.4%	154,836	SC 13D
Feb 13, 2023	topline capital management, llc	1.8%	144,645	SC 13G/A
Feb 14, 2022	topline capital management, llc	8.1%	570,478	SC 13G/A
Jun 11, 2021	topline capital management, llc	14.2%	542,240	SC 13G/A
Jun 10, 2021	topline capital management, llc	7.3%	281,383	SC 13G
Jan 08, 2021	sabby management, llc	12.%	0	SC 13G/A
Jan 23, 2020	sabby management, llc	6.53%	63,880	SC 13G/A

Recent SEC filings of NeuroMetrix Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	S-8	Employee Benefits Plan
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 01, 2024	8-K	Current Report
Apr 30, 2024	4/A	Insider Trading

Peers (Alternatives to NeuroMetrix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.9B	40.3B	-3.99%	-4.43%	32.33	4.51	-2.84%	-3.08%
BDX	68.5B	19.7B	1.04%	-5.28%	51.42	3.48	4.82%	-17.56%
ALGN	21.1B	3.9B	-8.05%	-4.13%	45.63	5.39	5.72%	46.72%
BAX	18.1B	14.9B	-11.51%	-17.62%	6.82	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.53%	24.43%	31.2	2.75	6.16%	35.06%
HSIC	9.6B	12.5B	5.70%	-3.02%	24.67	0.77	-0.61%	-18.83%
BIO	8.6B	2.6B	0.13%	-21.80%	-26.61	3.29	-6.25%	-68.62%
XRAY	5.9B	3.9B	-8.58%	-30.13%	-62.71	1.49	0.23%	91.03%
AXNX	3.5B	387.1M	0.52%	27.70%	-216.75	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	1.85%	-3.48%	11.96	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-0.51%	-11.36%	-1.88	0.4	7.94%	-1661.78%
ANIK	386.7M	169.3M	3.28%	2.59%	-5.03	2.28	7.49%	-244.90%
ANGO	254.7M	324.0M	0.79%	-32.56%	-1.32	0.79	-3.19%	-337.41%
APYX	48.8M	50.5M	2.90%	-74.91%	-2.14	0.97	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.41%	25.00%	-0.09	0.28	5.77%	8.23%

NeuroMetrix Inc News

Latest updates

NeuroMetrix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-17.0%	1,094	1,318	1,203	1,656	1,725	1,847	1,968	2,138	2,302	1,820	2,064	2,213	2,155	1,810	2,036	1,360	2,172	887	2,088	1,382	5,735
Cost Of Revenue	22.7%	577	470	421	536	526	617	694	686	509	577	620	558	576	476	538	495	620	645	914	3,144	2,324
Gross Profit	-39.0%	517	848	782	1,119	1,198	1,230	1,274	1,452	1,794	1,243	1,445	1,655	1,579	1,334	1,499	865	1,552	1,062	1,174	-789	799
Operating Expenses	39.4%	3,771	2,705	2,743	2,743	2,908	2,087	2,987	2,662	2,756	2,247	2,132	2,187	1,639	1,660	1,757	1,718	2,210	2,721	2,586	3,973	4,500
S&GA Expenses	23.4%	1,062	861	944	745	816	630	810	567	859	514	442	269	394	292	341	379	424	708	648	1,374	2,025
R&D Expenses	28.8%	944	732	593	754	699	538	1,075	916	711	997	725	642	233	545	653	660	534	737	475	1,035	855
EBITDA Margin	-12.0%	-1.89*	-1.69*	-1.55*	-1.38*	-1.30*	-1.21*	-1.21*	-1.20*	-1.18*	-1.20*	-1.20*	-1.20*	-	-	-	-	-	-	-	-	-
EBT Margin	-12.0%	-1.90*	-1.70*	-1.56*	-1.39*	-1.30*	-1.21*	-1.22*	-1.20*	-1.19*	-1.21*	-1.21*	-1.22*	-	-	-	-	-	-	-	-	-
Net Income	-83.7%	-3,029	-1,649	-1,768	-1,537	-1,574	-691	-1,606	-1,159	-958	-1,003	-687	-531	-59.78	-325	-257	-851	-657	-1,056	-1,404	-3,362	2,051
Net Income Margin	-36.9%	-1.52*	-1.11*	-0.87*	-0.75*	-0.66*	-0.53*	-0.57*	-0.46*	-0.38*	-0.28*	-0.19*	-0.14*	-	-	-	-	-	-	-	-	-
Free Cashflow	-42.2%	-2,126	-1,495	-2,200	-1,451	-1,121	-1,482	-2,237	-846	-745	-519	-1,034	-596	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.5%	20,664	21,424	21,287	22,774	23,610	24,670	24,032	25,257	26,248	24,888	26,294	10,769	7,721	7,995	8,340	8,606	6,206	6,894	8,507	10,814	13,907
Current Assets	-3.4%	20,152	20,854	20,706	22,289	23,086	24,107	23,432	24,627	25,587	24,188	25,560	10,031	6,965	7,090	7,290	7,404	4,878	5,431	6,636	8,849	11,630
Cash Equivalents	-27.3%	1,260	1,732	1,461	1,863	2,377	4,335	1,772	6,002	23,769	22,572	23,214	8,364	5,145	5,226	4,929	5,435	2,816	3,126	3,187	4,958	7,201
Inventory	-5.6%	1,471	1,559	1,667	1,584	1,748	1,615	1,057	869	712	707	997	1,029	980	1,051	1,050	1,192	1,154	1,164	1,079	2,063	2,494
Net PPE	-8.5%	269	293	273	145	155	166	176	179	184	199	205	187	183	183	206	238	250	273	299	289	376
Liabilities	43.1%	1,908	1,333	1,383	1,362	1,597	1,314	2,066	1,846	2,010	1,672	2,066	1,934	2,460	2,747	2,968	3,117	3,692	4,363	4,933	5,957	5,714
Current Liabilities	48.9%	1,847	1,241	1,260	1,210	1,417	1,106	1,832	1,588	1,727	1,366	1,736	1,583	2,088	2,285	2,386	2,419	2,882	3,447	3,915	4,840	4,503
Shareholder's Equity	-6.6%	18,756	20,091	19,904	21,411	22,013	23,356	21,966	23,411	24,238	23,216	24,228	8,835	5,261	5,248	5,372	5,489	2,514	2,530	3,574	4,858	8,192
Retained Earnings	-1.4%	-213,138	-210,109	-208,459	-206,691	-205,154	-203,579	-202,888	-201,281	-200,121	-199,163	-198,160	-197,473	-196,941	-196,881	-196,600	-196,300	-195,446	-194,789	-193,732	-192,300	-189,000
Additional Paid-In Capital	0.7%	231,648	229,960	228,156	227,933	227,100	226,935	224,854	224,692	224,359	222,378	222,388	206,308	202,202	202,129	201,927	201,787	197,961	197,320	197,305	197,185	197,158
Shares Outstanding	30.3%	1,987	1,525	1,074	1,072	973	971	892	892	876	835	831	631	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	8,184	-	-	-	25,919	-	16,975	-	-	-	-	-	7,691	-	-	-	3,893	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-43.5%	-2,081	-1,450	-2,061	-1,451	-1,121	-1,482	-2,227	-838	-740	-512	-992	-534	-33.79	281	-516	-1,068	-763	-61.14	-1,737	-2,242	420
Share Based Compensation	20.0%	216	180	221	133	165	168	162	109	38.00	113	196	320	69.00	186	140	129	144	6.00	120	20.00	44.00
Cashflow From Investing	41.1%	138	98.00	1,658	237	-836	2,133	-2,002	-16,936	-5.39	-6.67	-41.77	-61.82	-21.45	-	11.00	-10.50	-	-6.90	-33.59	-7.59	-
Cashflow From Financing	-9.4%	1,471	1,624	1.00	700	-	1,913	-	8.00	1,943	-122	15,884	3,816	-25.80	16.00	-	3,698	453	8.00	-	7.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NURO Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue from Contract with Customer, Including Assessed Tax	$ 5,901,425	$ 8,256,073
Cost of Revenue	1,954,012	2,505,833
Gross Profit, Total	3,947,413	5,750,240
Operating Expenses [Abstract]
Research and Development Expense	2,777,960	3,239,725
Selling and Marketing Expense	3,365,265	2,865,615
General and Administrative Expense	4,955,709	4,386,666
Operating Expenses, Total	11,098,934	10,492,006
Operating Income (Loss), Total	(7,151,521)	(4,741,766)
Net Income (Loss) Available to Common Stockholders, Basic	(6,529,487)	(4,416,609)
Net Income (Loss) Attributable to Parent, Total	$ (6,529,487)	$ (4,416,609)
Earnings Per Share, Diluted	$ (6.27)	$ (4.97)
Earnings Per Share, Basic	$ (6.27)	$ (4.97)
Investment Income, Interest	$ 257,105	$ 325,157
Other Nonoperating Income	364,929	0
Nonoperating Income (Expense)	$ 622,034	$ 325,157

NURO Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Assets, Current [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 1,731,946	$ 4,335,020
Debt Securities, Available-for-Sale	16,265,205	0
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss	0	16,864,707
Accounts Receivable, after Allowance for Credit Loss, Current	518,824	646,771
Inventory, Net	1,559,428	1,614,987
Prepaid Expense and Other Assets, Current	779,039	645,502
Assets, Current, Total	20,854,442	24,106,987
Operating Lease, Right-of-Use Asset	250,150	370,609
Assets, Total	21,424,441	24,669,615
Other Assets, Noncurrent	26,400	26,400
Property, Plant and Equipment, Net	293,449	165,619
Liabilities, Current [Abstract]
Accounts Payable, Current	215,509	368,082
Accrued Liabilities, Current	876,739	589,939
Operating Lease, Liability, Current	148,391	148,391
Liabilities, Current, Total	1,240,639	1,106,412
Liabilities, Total	1,333,124	1,313,928
Operating Lease, Liability, Noncurrent	92,485	207,516
Commitments and Contingencies
Stockholders' Equity Attributable to Parent [Abstract]
Additional Paid in Capital	229,960,346	226,935,456
Accumulated Other Comprehensive Income (Loss), Net of Tax	240,171	0
Retained Earnings (Accumulated Deficit)	(210,109,353)	(203,579,866)
Stockholders' Equity Attributable to Parent, Total	20,091,317	23,355,687
Liabilities and Equity, Total	$ 21,424,441	$ 24,669,615
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	25,000,000	25,000,000
Common Stock, Shares, Issued	1,524,939	971,492
Common Stock, Shares, Outstanding	1,524,939	971,492
Common Stock, Value, Issued	$ 152	$ 96
Convertible Preferred Stock [Member]
Stockholders' Equity Attributable to Parent [Abstract]
Preferred Stock, Value, Issued	1	1
Preferred Non-Convertible Stock
Stockholders' Equity Attributable to Parent [Abstract]
Preferred Stock, Value, Issued	$ 0	$ 0

About NeuroMetrix Inc

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

CEO	Dr. Shai N. Gozani M.D., Ph.D.
WEBSITE	neurometrix.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	27

NeuroMetrix Inc Frequently Asked Questions

What is the ticker symbol for NeuroMetrix Inc? What does NURO stand for in stocks?

NURO is the stock ticker symbol of NeuroMetrix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroMetrix Inc (NURO)?

As of Wed May 15 2024, market cap of NeuroMetrix Inc is 8.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NURO stock?

You can check NURO's fair value in chart for subscribers.

What is the fair value of NURO stock?

You can check NURO's fair value in chart for subscribers. The fair value of NeuroMetrix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeuroMetrix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NURO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeuroMetrix Inc a good stock to buy?

The fair value guage provides a quick view whether NURO is over valued or under valued. Whether NeuroMetrix Inc is cheap or expensive depends on the assumptions which impact NeuroMetrix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NURO.

What is NeuroMetrix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, NURO's PE ratio (Price to Earnings) is -1.06 and Price to Sales (PS) ratio is 1.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NURO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NeuroMetrix Inc's stock?

In the past 10 years, NeuroMetrix Inc has provided -0.387 (multiply by 100 for percentage) rate of return.